+91 80 2808 2808
Biocon  /  Investor Relations  /  Shareholder Services  /  Investor FAQ


Corporate Information

Biocon is a global provider of innovative biopharmaceutical products and research services that span the entire drug value chain: pre-clinical discovery to clinical development to commercialisation. The Biocon group of companies consists of Biocon Limited, the flagship company and its sixteen subsidiaries.
The Small Molecules vertical offers a strong portfolio of differentiated APIs across statins, immunosuppressants, specialty molecules and includes our Generic formulations business

The Biologics vertical comprises our Novel Biologics and Biosimilars, including rh-insulin, insulin analogs, monoclonal antibodies and recombinant proteins.

The Branded Formulations business includes our finished dosages business in India and overseas including UAE.

Custom & Clinical Research Services

Biocon provides contract research services to overseas and domestic customers in the following areas:

– Molecular Biology
– Biologics
– Synthetic Chemistry
– Bioinformatics
– Clinical research on well-defined and   characterised patients   suffering from chronic diseases such as diabetes,

osteoporosis, asthma, etc.

Biocon has its corporate and registered office at Bangalore.
20th KM, Hosur Road
Electronic City PO
Bangalore – 560 100
Ph +91 80 2808 2808
Fax +91 80 2852 3423

Biocon was incorporated on November 29, 1978 in Bangalore, India.

Team Biocon comprises of 12,000+ employees (as on March 31, 2020) in various fields, with a strong scientist portfolio.

Amount in Rs. Million
Rupees Crores FY22 FY23
 Revenues 83,967 Mn 115,501 Mn
 Net Profit for the period 7,716 Mn 6,430 Mn


To obtain the financial results of the company, please refer to our website under the Investor Relations section here. Alternatively, the same is also available at the website of National Stock Exchange (NSE) and Mumbai Stock Exchange (BSE).
The results of the company are also published in leading Business Dailies.

Biocon’s Board consists of:
Ms. Kiran Mazumdar-Shaw, Executive Chairperson
Mr. Siddharth Mittal, CEO and Managing Director
Prof Ravi Mazumdar, Non-Executive Director
Mr. M. Damodaran, Independent and Non-Executive Director
Mr. Bobby Kanubhai Parikh, Independent and Non-Executive Director
Mr. Eric Mazumdar, Non-Executive Director
Ms. Naina Lal Kidwai, Independent and Non-Executive Director
Mr. Peter Bains, Independent and Non-Executive Director
Ms. Rekha Mehrotra Menon, Additional Director (Category – Independent Director)

Equity Shares Information

In March 2004, Biocon went public with an IPO of 10,000,000 fresh equity shares of Rs. 5 each at a price of Rs. 315 per share

Name of Exchange Code
 National Stock Exchange, Mumbai (NSE) BIOCON
 Mumbai Stock Exchange, (BSE) 532523

Details of shareholding pattern of the company is available on our website in the Investor Relations Section here. The same is also available on the NSE and BSE websites.

The Company has been consistently paying dividend since 2004. For the fiscal year 2022-23, the Board of Directors has recommended a final dividend of Rs. 1.50 per share, subject to shareholders’ approval at the ensuing Annual General Meeting.

The broad shareholding pattern of Biocon as on Dec. 31, 2019
 ESOP Trust 1.27%
 Promoters 60.67%
 Public, Institutional and Others 38.07%

Investor Calendar

The tentative calendar for the financial results for the fiscal year 2021-22 and 2022-23 is as follows:
Q4 FY 2022-23 To be Released on May 23, 2023
Q3 FY 2022-23 To be Released on February 14, 2023
Q2 FY 2022-23 Released on November 14, 2022
Q1 FY 2022-23 Released on July 27, 2022
Q4 FY 2021-22 Released on April 28, 2022
Q3 FY 2021-22 Released on January 21, 2022
Q2 FY 2021-22 Released on October 22, 2021
Q1 FY 2021-22 Released on July 23, 2021
 Q4 FY 2020-21 Released on April 29, 2021

The Annual General Meeting (AGM) of the Company for the year 2022-23 is scheduled for August 11, 2023.

Yes. Biocon follows quiet periods prior to declaration of its quarterly results ie. starting from the 1st day immediately following the relevant calendar quarter till the second trading day after disclosure of such quarterly/ annual financial results. During this time, the Company or any of its officials will not discuss earnings expectations with any external parties.

Dematerialisation of shares

Dematerialisation (or Demat) signifies the conversion of a share certificate from its present physical form to electronic form for the same number of holdings.
It is a direct application of scope provided by the tremendous progress made in the area of Information Technology, whereby voluminous and cumbersome paper work involved in the scrip based system is eliminated.
It offers scope for paperless trading through state-of-the-art technology, whereby share transactions and transfers are processed electronically without involving any share certificate or transfer deed after the share certificates have been converted from physical to electronic form.
Demat attempts to avoid the time consuming and complex process of getting shares transferred in the name of buyers and also aims to shirk inherent problems of bad deliveries, delay in processing, fraudulent interception in postal transit, etc.
Dematerialisation of shares is optional and an investor can still hold shares in the physical form. However, he/she has to demat the shares if he/she wishes to sell the same through the Stock Exchanges. Similarly, if an investor purchases shares, he/she will get delivery of the shares in demat form.
The Depositories Act, 1996 has been enacted to regulate the matters related and incidental to the operation of Depositories and demat operations. Two Depositories are in operation – National Securities Depository Limited (NSDL) and Central Depository Services Limited (CDSL).

The operations in the Depository System involve the Depositories, Depository Participants, Company/Registrars and Investors.
A Depository (NSDL and CDSL) is an organisation like a Central Bank, i.e. Reserve Bank where the securities of an investor are held in the electronic form through Depository Participants.
A Depository Participant is the agent of the Depository and is the medium through which shares are held in the electronic form. They are also the representatives of the Investor, providing the link between the Investor and the Company/ Registrar through the Depository.
To draw an analogy, the Depository System functions in a manner similar to a banking system. A bank holds funds in accounts whereas a Depository holds securities in accounts for its clients. A bank transfers funds between accounts while a Depository transfers securities between accounts.
In both systems, the transfer of funds or securities occurs without the actual handling of funds or securities. Both, the bank and the Depository, are accountable for the safe keeping of funds and securities respectively. The Company signs an Agreement with NSDL/CDSL (the depositories) and installs the necessary hardware/software for operations.

First, please open an account with a Depository Participant (DP) and obtain a unique Client ID number. Thereafter, kindly fill up a Dematerialisation Request Form (DRF) provided by the DP and surrender the physical shares intended to be dematted to the DP.
Upon receipt of the shares and the DRF, the DP will send electronic requests through the Depository to the Company/Registrar for confirmation of demat. Each request will bear a unique transaction number.
Simultaneously, the DP will surrender the DRF and the shares to the Company with a covering letter requesting the Company/Registrar to confirm the demat. After verifying the documents received from the DP, the Company/Registrar will confirm the demat to the Depository.
This confirmation will be passed on from the Depository to the DP, which holds your account. After receiving this confirmation from the Depository, the DP will credit the account with the dematerialised shares. The DP will then hold the shares in the dematerialised form on your behalf and you become the beneficial owner of these dematerialised shares.

If you hold shares in the electronic form, you have the option of converting your holding to the physical form by submitting a Rematerialisation Request Form (RRF) through your DP.
The procedure is as follows:
Shareholders should submit the duly filled in Rematerialisation Request Form (RRF) to the concerned DP.
DP intimates the relevant Depository of such requests.
DP submits RRF to the Company’s R&TA.
Depository confirms rematerialisation request to the Company’s R&TA.
The Company’s R&TA updates accounts and prints certificate(s) and informs the Depository.
Depository updates the Beneficiary Account of the shareholder by deleting the shares so rematerialised.
Share certificate(s) is despatched to the shareholder by Company’s R&TA.

The charges for demat have to be borne by the shareholder. The charges differ from DP to DP and therefore you will have to contact your DP for details regarding the same.

Yes. With effect from 5th April, 1999 it has become mandatory to trade shares in demat form. However, you can exercise the option of holding the shares in physical form.

On the Record date, the Depository Participants will provide a list of demat account holders indicating the number of shares held in electronic form (known as Benpos – Beneficiary Position). On the basis of Benpos, the Company will make dividend payments in favour of the demat account holders.
The rights of the shareholders holding shares in demat form are at par with holders of shares in physical form. Hence, you will be eligible to procure the Annual Report and can rightfully attend the AGM as a shareholder.
It is advisable to register your NACH mandate with your Depository Participant to enable us credit all your dividends electronically.

Common risk factors applicable to trading in physical shares like mismatch in signatures, loss in postal transit, etc., are absent since dematted shares are traded scrip-less.
In case of any dispute, please contact your Depository Participant would have to be approached for resolution of the same.

As per the Depository Regulations, the Company/ RTA is obliged to take on record the details of shareholders (having shares in dematerialised form) furnished by the concerned Depository Participant. The Company/ RTA cannot make any change in such records received from the Depository.

Depositories provide “Transposition cum Demat facility” to help joint holders to dematerialise securities in different sequence of names. For this purpose, DRF and Transposition Form should be submitted to the DP.

  • Attested / Notarised copy of death certificate of the deceased shareholder.
  • Request letter duly signed by the surviving share holders.
  • Self attested copies of PAN card and address proofs of the surviving share holders
  • Original Share certificates

NSDL and CDSL have launched SMS Alert facility for demat account holders whereby the investors can receive alerts for debits and credits in their demat accounts. Under this facility, investors can receive alerts, a day after such debits (transfers) / credits take place. These alerts are sent to those account holders who have provided their mobile numbers to their DPs. Alerts for debits are sent, if the debits (transfers) are up to five ISINs in a day. In case debits (transfers) are for more than five ISINs, alerts are sent with a message that debits for more than five ISINs have taken place and that the investor can check the details with the DP.

Leaving the Biocon site!

You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>